Shares of Cohance Lifesciences (formerly Suven Life Sciences Ltd), a contract research services company, are under scrutiny after the Telangana Pollution Control Board (TGPCB) issued a directive to close its manufacturing facility in Suryapet, Telangana.
The closure order stems from a tragic industrial accident that occurred during the manufacturing process. One employee on duty at the facility was exposed and subsequently succumbed to their injuries despite receiving extensive medical care in Hyderabad.
Company Response and Remedial Actions
Cohance Lifesciences, which specializes in CDMO, API platforms, and clinical solutions, has confirmed that it immediately initiated appropriate corrective and preventive measures to address the observations made by the TGPCB. The company stated its intention to promptly submit the necessary representations and ensure compliance to the TGPCB, aiming to secure a swift cancellation of the closure order and allow the site to resume operations.
The company has committed to keeping stock exchanges informed of any significant developments regarding the situation.
Market Impact
Following the news, Cohance shares settled at Rs 449 on Thursday. Analyst estimates project a 12-month target of Rs 472, suggesting a potential upside of 5.2 percent from the current price, based on six analyst assessments. Investors are closely monitoring the company's progress in resolving the regulatory issues and resuming full operations at the affected site.